Eli Lilly has purchased an integrated suite of cellular screening technology and licenses from Amersham to help in the identification of potential therapeutics in its drug discovery program.
At the core of the purchase is one of Amerham's IN Cell Analyzer 3000 high-throughput sub-cellular imaging system for performing live and fixed cellular assays very rapidly and at high resolution. However,Lilly has also signed an agreement with Amersham for rights to its Aequorea victoria Green Fluorescent Protein (GFP) reagent, used to build up a detailed picture of the distribution, trafficking and function of proteins within cells, and to evaluate how drug candidates affect these processes in a cellular environment.
Furthermore, Lilly has secured rights to operate under BioImage's Redistribution patent portfolio for monitoring intracellular signalling pathways, including protein translocation. Amersham secured rights to this portfolio via a licensing agreement concluded in December 2000.
"Utilising the advanced imaging quality and speed of the IN Cell Analyzer 3000 system in conjunction with the Aequorea victoria GFP and Redistribution helps speed cellular screening capability and, ultimately, aid the discovery of new pharmaceuticals by examining disease-related targets in an informative biological context," said Amersham in a statement.